Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
December 14 2021 - 9:00AM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the
promotion of Mark Schneyer to Executive Vice President, Chief
Financial Officer (CFO), effective immediately. Mr. Schneyer has
served as the company’s interim CFO since September 2021, while
retaining his responsibilities as Acadia’s head of business
development and Chief Business Officer. Mr. Schneyer’s
responsibilities as CFO will include the functional areas of
finance, accounting, investor relations, and business development.
Mr. Schneyer will continue to report to Steve Davis, Chief
Executive Officer, and will remain a member of the company’s
Executive Management Committee.
“Mark is a highly valuable thought partner who has demonstrated
strong leadership across the breadth of our business,” said Steve
Davis, Chief Executive Officer. “I’m very excited to further
leverage Mark’s robust experience in corporate finance and
strategic transactions as we realize the promise of Acadia’s
near-term opportunities and execute on our long-term strategy.”
Since joining Acadia in 2020, Mr. Schneyer has been instrumental
in developing long-term strategic growth initiatives focused on
expanding the breadth of transactions the company evaluates. He led
the effort to acquire CerSci Therapeutics in late 2020 which
brought in a Phase 2 ready pain program with a first-in-class
mechanism.
“I look forward to serving as Acadia’s CFO and working with our
talented teams across the company to drive our continued commercial
success, advance our research and development pipeline, expand our
portfolio, engage with the investment community, and serve the
patients and families who can benefit from our innovative approach
to meeting the unmet needs in neuroscience,” said Mr. Schneyer.
Mr. Schneyer joined Acadia from Pfizer Inc. where he was most
recently Vice President, Business Development for the Upjohn
division. He joined Pfizer’s Worldwide Business Development
organization in 2011 and served in various business development
positions of increasing responsibility overseeing strategic
transactions spanning licensing agreements, product acquisitions
and divestitures, strategic collaborations and company
acquisitions. Prior to Pfizer, Mr. Schneyer was an investment
banker at Lazard and advised boards of directors and senior
management teams in the healthcare sector.
Mr. Schneyer earned a Bachelor of Science in economics with a
concentration in finance from the Wharton School of the University
of Pennsylvania.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For more than 25 years we have been working at the forefront
of healthcare to bring vital solutions to people who need them
most. We developed and commercialized the first and only approved
therapy for hallucinations and delusions associated with
Parkinson’s disease psychosis. Our late-stage development efforts
are focused on treating psychosis in patients with dementia, the
negative symptoms of schizophrenia and Rett syndrome. Our
early-stage development efforts are focused on novel approaches to
pain management, cognition and neuropsychiatric symptoms in central
nervous system disorders. For more information, visit us at
www.acadia-pharm.com and follow us on LinkedIn and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211214005394/en/
Media Contact: Acadia Pharmaceuticals Inc. Deb Kazenelson (818)
395-3043 media@acadia-pharm.com
Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA
(858) 261-2771 ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024